Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-E2-A10E-01A-21R-A10J-07

— · B

596b4c76-4e70-510e-8910-26a6285a2c3d

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
B
subtype
B
overall_survival_months
29

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • PROTEIN_SECRETION+0.350
  • INTERFERON_ALPHA_RESPONSE+0.340
  • UV_RESPONSE_DN+0.290
  • TGF_BETA_SIGNALING+0.260
  • ANDROGEN_RESPONSE+0.220
  • ESTROGEN_RESPONSE_EARLY+0.220
  • PI3K_AKT_MTOR_SIGNALING+0.180
  • NOTCH_SIGNALING+0.140
  • HEME_METABOLISM+0.130
  • TNFA_SIGNALING_VIA_NFKB+0.130

Top 10 suppressed

  • MYC_TARGETS_V2-0.300
  • ALLOGRAFT_REJECTION-0.280
  • SPERMATOGENESIS-0.230
  • E2F_TARGETS-0.180
  • MYOGENESIS-0.180
  • WNT_BETA_CATENIN_SIGNALING-0.180
  • G2M_CHECKPOINT-0.170
  • APICAL_SURFACE-0.150
  • CHOLESTEROL_HOMEOSTASIS-0.140
  • DNA_REPAIR-0.110

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-A2-A0YC-01A-11R-A109-07
breast-umap@18
—B0.728
2C3L-02549
lung-landscapes@6
—cohortA10.699
3SRR4296096
lung-landscapes@6
—cohortA10.684
4MDT-AP-2642
medullo-epn-umap@date-based
MedMedulloblastoma0.678
5TCGA-AN-A0XP-01A-11R-A109-07
breast-umap@18
—B0.672
6SRR6013523
lung-landscapes@6
—cohortA10.668
7TCGA-44-6146-01A-11R-A278-07
lung-landscapes@6
—cohortA10.668
8SRR23036898
head-neck@1
——0.661
9TCGA-44-6146-01A-11R-1755-07
lung-landscapes@6
—cohortA10.660
10TCGA-BH-A0B1-01A-12R-A056-07
breast-umap@18
—B0.654

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
PROTEIN_SECRETION0.350Remibrutinib— uncovered
INTERFERON_ALPHA_RESPONSE0.340Inavolisib— uncovered
UV_RESPONSE_DN0.290Inavolisib— uncovered
TGF_BETA_SIGNALING0.260Inavolisib— uncovered
ANDROGEN_RESPONSE0.220Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.220Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.180Inavolisib— uncovered
NOTCH_SIGNALING0.140Inavolisib— uncovered
HEME_METABOLISM0.130Temsirolimus— uncovered
TNFA_SIGNALING_VIA_NFKB0.130Inavolisib— uncovered
FATTY_ACID_METABOLISM0.120Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.120Idelalisib— uncovered
ADIPOGENESIS0.110Inavolisib— uncovered
APOPTOSIS0.110Idelalisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.110Remibrutinib— uncovered
HEDGEHOG_SIGNALING0.100Inavolisib— uncovered
UV_RESPONSE_UP0.100Idelalisib— uncovered
IL6_JAK_STAT3_SIGNALING0.080Inavolisib— uncovered
MITOTIC_SPINDLE0.080Inavolisib— uncovered
PANCREAS_BETA_CELLS0.070Cobimetinib— uncovered